NSABP B-52: A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or Without Estrogen Deprivation
This study is for women, who have breast cancer that is both hormone positive and HER2 positive.
The purpose of this study is to compare the effects of using hormone drugs with the usual chemotherapy drugs to using the chemotherapy drugs alone given before surgery. For example, hormone drugs given with chemotherapy drugs could shrink the cancer but they could also cause side effects. This study will allow the researchers to know whether giving hormone drugs with chemotherapy drugs is better, the same, or worse than giving hormone drugs after chemotherapy drugs. Hormone drugs are commonly used for breast cancer but are usually not used until after you receive chemotherapy drugs. Receiving hormone drugs with chemotherapy drugs is the study question.
Patients will be followed for approximately 5 years.
*An additional biopsy of the breast cancer tissue is required.